Agreements reached under this partnership
Business alliance- 1
Grant of exclusive rights in Japan for the sales and promotion of the product
- 2
丸石製薬 will handle sales and promotion of the product as the primary distributor
- 3
The Company will handle development, obtaining marketing approval, manufacturing and supply of the product
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The ¥100 million upfront payment is scheduled to be recognized as revenue in the fiscal year ending September 2026. Development milestone payments and post-launch royalties are scheduled to be recognized based on future development progress, the timing of marketing approval and sales of the product.
| Item | Details |
|---|---|
| Name of alliance partner | 丸石製薬株式会社 |
| Alliance partner's business activities | Manufacturing and marketing of pharmaceuticals and other products |
| Alliance partner's location | Tsurumi-ku, Osaka |
| Alliance partner's capital | ¥285 million |
| Alliance partner's net sales | FY2025 ¥48.3 billion |
| Type of alliance | Business alliance |
| Details of the alliance | Grant of exclusive rights in Japan for the sales and promotion of the product, 丸石製薬 will handle sales and promotion of the product as the primary distributor, The Company will handle development, obtaining marketing approval, manufacturing and supply of the product |
| Contract Date | 16 September 2026 |
| Impact on Business Performance | The ¥100 million upfront payment is scheduled to be recognized as revenue in the fiscal year ending September 2026. Development milestone payments and post-launch royalties are scheduled to be recognized based on future development progress, the timing of marketing approval and sales of the product. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because it was determined that 丸石製薬’s expertise and experience as a specialty pharmaceutical company, together with its domestic sales network, would contribute to market penetration and stable supply following the launch of the product. The agreement will also secure revenue opportunities from an upfront payment, development milestones and post-launch royalties, thereby strengthening the business foundation.